Cardioprotective of Electroacupuncture Pretreatment in Patients Underwent Coronary Stenting: A Prospective, Multicenter, Randomized Control Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Myocardial Injury
- Sponsor
- Xijing Hospital
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- The primary outcome was assessing whether EA pretreatment before elective PCI reduced cTnI concentration at 48 hours.
- Last Updated
- 14 years ago
Overview
Brief Summary
Myocyte necrosis as a result of elective percutaneous coronary intervention (PCI) occurs in approximately one third of cases and is associated with subsequent cardiovascular events. This study assesses the ability of electroacupuncture (EA) pretreatment to attenuate cardiac troponin I (cTnI) release after elective PCI.
Detailed Description
Elective percutaneous coronary intervention (PCI) is associated with troponin release in approximately one third of cases.Troponin release is a sensitive and specific marker of myocyte necrosis and infarction resulting from a form of ischemia/reperfusion injury, downstream embolization of atheromatous material, and coronary side-branch occlusion. A number of studies have demonstrated that procedure-related troponin release is associated with subsequent cardiovascular events. Transient sublethal episodes of ischemia before a prolonged ischemia/reperfusion injury, known as ischemic preconditioning (IPC), have been shown to reduce the extent of myocardial infarction (MI).Electroacupuncture (EA) stimulus, as a pretreatment method, limits MI size in animal models. However, there are limited outcome to demonstrate protection from EA pretreatment during PCI. The present study investigated the ability of EA pretreatment to attenuate cardiac troponin I (cTnI) release after elective PCI in a single-center, randomized controlled trial.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All patients \> 18 of age who are undergoing elective PCI and are able to give informed consent are eligible for study.
Exclusion Criteria
- •Emergency PCI,
- •Elevation of cTnI before PCI taken at the preadmission clinic,
- •Women of child-bearing age,
- •Nicorandil or glibenclamide use (preconditioning-mimetic and preconditioning blocking medication, respectively), and
- •Severe comorbidity (estimated life expectancy \< 6 months).
Outcomes
Primary Outcomes
The primary outcome was assessing whether EA pretreatment before elective PCI reduced cTnI concentration at 48 hours.
Time Frame: 48 hours after PCI
Secondary Outcomes
- Secondary outcomes were the effect of EA pretreatment on ischemic symptoms, ECG evidence of ischemia during coronary balloon occlusion, CRP,and major adverse cardiac events (MACE) at 6 months.(six months of PCI follow-up.)